Key result
Neutralizing antibodies may abrogate the clinical efficacy of interferon beta in multiple sclerosis.
Why the study?
Neutralising anti-Interferon Beta Antibodies frequently develop in relapsing remitting Multiple Sclerosis patients treated with Interferon Beta and may reduce drug efficacy, necessitating reliable quantification and management strategies.
Answers are grounded in this paper and cite their sources.
This review discusses the development, quantification, and management of neutralizing anti-interferon beta antibodies in patients with relapsing-remitting multiple sclerosis to optimize therapy.
Interferon Beta is well established as a first line agent to treat relapsing remitting Multiple Sclerosis. It frequently induces the formation of neutralising anti-Interferon Beta Antibodies (Nabs) which may abrogate the clinical efficacy of the drug. Numerous studies have shown a loss of bioactivity of the drug in the presence of Nabs. The focus has shifted to reliable quantification of Nabs and their appropriate incorporation into clinical practice. Here we review the development and persistence of Nabs, the effect on Interferon beta bioactivity, clinical and para-clinical autocome measures in trials, Nab assays and discuss management strategies to optimise the use of Interferon beta in relapsing remitting MS.
No takes yet. Share an insight, caveat, or question.
Farrell et al. (2007) conducted a review in relapsing remitting Multiple Sclerosis. Interferon Beta was evaluated. This review discusses the development, persistence, and management of neutralizing anti-Interferon Beta antibodies, which may abrogate the clinical efficacy of Interferon Beta in multiple sclerosis.
Synapse has enriched 10 related papers. Consider them for comparative context: